Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.
Meng Hsuan KuoChih-Wei TsengMing-Chi LuChien-Hsueh TungKuo-Chih TsengKuang-Yung HuangChi-Hui LeeNing-Sheng LaiPublished in: Digestive diseases and sciences (2021)
Tocilizumab is widely used in treating rheumatoid arthritis and has the potential to reduce the mortality rate among severe COVID-19 patients. However, HBV reactivation needs to be considered. HBsAg+ patients have a high risk of HBV reactivation, which could be prevented by antiviral prophylaxis. Although the risk of reactivation is low in HBsAg-/HBcAb+ patients, strict monitoring is necessary.
Keyphrases
- hepatitis b virus
- rheumatoid arthritis
- end stage renal disease
- patients undergoing
- ejection fraction
- newly diagnosed
- liver failure
- chronic kidney disease
- disease activity
- peritoneal dialysis
- sars cov
- patient reported outcomes
- early onset
- coronary artery disease
- risk assessment
- rheumatoid arthritis patients
- cardiovascular events
- ankylosing spondylitis
- systemic lupus erythematosus
- systemic sclerosis